Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9UMR3
UPID:
TBX20_HUMAN
Alternative names:
-
Alternative UPACC:
Q9UMR3; A4D1Y6; Q000T4; Q0IJ70; Q0VAS1; Q9Y2N5
Background:
T-box transcription factor TBX20 plays a pivotal role in cardiac development, acting as both a transcriptional activator and repressor. Its functions are crucial for the maintenance of functional and structural phenotypes in the adult heart, highlighting its significance in cardiac biology.
Therapeutic significance:
Given its involvement in Atrial septal defect 4, a congenital heart malformation, TBX20 is a prime target for therapeutic intervention. Understanding the role of T-box transcription factor TBX20 could open doors to potential therapeutic strategies, offering hope for patients with this and potentially other cardiac abnormalities.